MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative medicine, and its collaborators today reported in Regenerative Medicine that it has successfully used its proprietary hemangio-derived mesenchymal cell (HMCTM) technology to treat dogs with canine anal furunculosis (CAF), which shares many features with Crohn’s disease.